{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T13:11:33Z","timestamp":1780319493362,"version":"3.54.1"},"reference-count":80,"publisher":"Informa UK Limited","issue":"6","funder":[{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Delivery"],"published-print":{"date-parts":[[2026,6,3]]},"DOI":"10.1080\/17425247.2026.2652029","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T09:40:31Z","timestamp":1775468431000},"page":"1107-1117","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["An update on the port delivery system with ranibizumab for retinal diseases"],"prefix":"10.1080","volume":"23","author":[{"given":"Maya","family":"Samman","sequence":"first","affiliation":[{"name":"Midwestern University","place":["Glendale, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Khan","sequence":"additional","affiliation":[{"name":"University of Nevada","place":["Reno, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aamir A.","family":"Aziz","sequence":"additional","affiliation":[{"name":"University of Nevada","place":["Reno, USA"]},{"name":"University of Chicago","place":["Chicago, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riya","family":"Patel","sequence":"additional","affiliation":[{"name":"Collegiate High School","place":["Richmond, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arshad M.","family":"Khanani","sequence":"additional","affiliation":[{"name":"University of Nevada","place":["Reno, USA"]},{"name":"Sierra Eye Associates","place":["Reno, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,4,6]]},"reference":[{"key":"#cr-split#-e_1_3_4_3_1.1","unstructured":"Centers for Disease Control and Prevention. Prevalence estimates for age-related macular degeneration (AMD). Vision and Eye Health Surveillance System (VEHSS). [updated 2024 May 15"},{"key":"#cr-split#-e_1_3_4_3_1.2","unstructured":"cited 2025 Jul 29]. Available from: https:\/\/www.cdc.gov\/vision-health-data\/prevalence-estimates\/amd-prevalence.html"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2021.08.011"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-021-02088-0"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2021.01.003"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00265-2"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.26074"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.91a.24028"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10204666"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.3390\/vision9020035"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-2641"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19061816"},{"issue":"3","key":"e_1_3_4_14_1","first-page":"133","article-title":"Diabetic macular edema","volume":"59","author":"Musat O","year":"2015","unstructured":"Musat O, Cernat C, Labib M, et al. Diabetic macular edema. Rom J Ophthalmol. 2015;59(3):133\u2013136.","journal-title":"Rom J Ophthalmol"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2014.2854"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.4103\/ijo.IJO_1240_18"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.10-6518"},{"key":"e_1_3_4_18_1","unstructured":"American Society of Retina Specialists. Evidence-based guidelines for management of diabetic macular edema. [updated 2022; cited 2025 Jul 7]. Available from: https:\/\/www.asrs.org\/content\/documents\/evidence-based-guidelines-for-management-of-diabetic-macular-edema.pdf"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.22608\/APO.2017416"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.4997"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2024.4400"},{"key":"e_1_3_4_22_1","unstructured":"American Diabetes Association. What is retinopathy? [updated 2023; cited 2025 Aug 3]. Available from: https:\/\/diabetes.org\/health-wellness\/eye-health\/what-is-retinopathy"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054481"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.09.006"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2021.100111"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00010-1"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0000000000000657"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24119591"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054481"},{"key":"e_1_3_4_30_1","volume-title":"EYLEA (aflibercept injection)","author":"Regeneron Pharmaceuticals Inc","year":"2011","unstructured":"Regeneron Pharmaceuticals Inc. EYLEA (aflibercept injection) [package insert]. Tarrytown (NY): Regeneron Pharmaceuticals Inc.; 2011."},{"key":"e_1_3_4_31_1","unstructured":"Canadian Agency for Drugs and Technologies in Health. Clinical review report: brolucizumab (Beovu): treatment of neovascular (wet) age\u2011related macular degeneration (AMD). ON: CADTH; 2020 Jul. Chapter NBK565336."},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.11.011"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S427416"},{"key":"e_1_3_4_34_1","unstructured":"Amgen Inc. Eylea HD (aflibercept) injection [prescribing information]. Thousand Oaks (CA): Amgen Inc.; 2023 [cited 2025 Aug 24] Available from: https:\/\/www.pi.amgen.com\/-\/media\/Project\/Amgen\/Repository\/pi-amgen-com\/pavblu\/pavblu_fpi_english.pdf"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.5b00849"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.2290"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000002566"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012208.pub2"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2024.02.014"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-019-04362-7"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep39301"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S383101"},{"key":"e_1_3_4_43_1","volume-title":"SUSVIMO [package insert]","author":"Genentech, Inc","year":"2025","unstructured":"Genentech, Inc. SUSVIMO [package insert]. South San Francisco (CA): Genentech, Inc; 2025."},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0000000000000835"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2022-001104"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2022.03.005"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.3928\/23258160-20220415-03"},{"key":"e_1_3_4_48_1","unstructured":"Genentech Inc. Susvimo (ranibizumab injection) for intravitreal use via Susvimo ocular implant [Prescribing information]. South San Francisco (CA): Genentech Inc.; 2024 [cited 2025 Aug 28] Available from: https:\/\/www.gene.com\/download\/pdf\/susvimo_prescribing.pdf"},{"key":"e_1_3_4_49_1","volume-title":"Presented at: Annual Scientific Meeting of the American Society of Retina Specialists","author":"Kitchens J","year":"2023","unstructured":"Kitchens J, Khanani AM, Vicente A, et al. Key pearls of the refill-exchange procedure for the port delivery system with ranibizumab. Presented at: Annual Scientific Meeting of the American Society of Retina Specialists; Seattle, Washington; 2023."},{"key":"e_1_3_4_50_1","unstructured":"Genentech Inc. FDA approves Genentech\u2019s Susvimo\u2122 (ranibizumab injection) 100 mg\/mL via port delivery system for treatment of neovascular (wet) age\u2011related macular degeneration. Genentech Media Release. 2021 Oct 22. South San Francisco (CA)."},{"key":"e_1_3_4_51_1","volume-title":"Reintroduction of the port delivery system with ranibizumab: device updates. Genentech Medical information","author":"Genentech, Inc","year":"2024","unstructured":"Genentech, Inc. Reintroduction of the port delivery system with ranibizumab: device updates. Genentech Medical information. South San Francisco (CA): Genentech; 2024 Jul."},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2025.0001"},{"key":"e_1_3_4_53_1","unstructured":"Genentech Inc. FDA approves Genentech\u2019s Susvimo\u00ae (ranibizumab injection) 100 mg\/mL via port delivery system for treatment of diabetic macular edema. Genentech Media Release. 2025 Feb 4. South San Francisco (CA)."},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.14.4.8"},{"key":"e_1_3_4_55_1","unstructured":"Genentech Inc. FDA approves Genentech\u2019s Susvimo\u00ae (ranibizumab injection) 100 mg\/mL via port delivery system for treatment of diabetic retinopathy. Genentech Media Release. 2025 May 22. South San Francisco (CA)."},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.3390\/ma17010114"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1177\/0192623320968079"},{"key":"#cr-split#-e_1_3_4_58_1.1","unstructured":"Genentech Inc. A study to evaluate the efficacy and safety of ranibizumab delivered via the port delivery system in participants with neovascular age-related macular degeneration (Archway). ClinicalTrials.gov [Internet]. Identifier: NCT03677934. [updated 2024 Mar 4"},{"key":"#cr-split#-e_1_3_4_58_1.2","unstructured":"cited 2025 Jul 13]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03677934"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2021.09.016"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-023-00843-5"},{"key":"e_1_3_4_61_1","unstructured":"A study to evaluate efficacy safety & pharmacokinetics of the port delivery system (PDS) with ranibizumab in participants with diabetic macular edema (DME) compared with intravitreal ranibizumab; a substudy to evaluate the safety of re-implanting the PDS with ranibizumab in participants with DME (Pagoda). Identifier: NCT04108156. ClinicalTrials.gov [Internet]. [updated 2024 Sep 26; cited 2025 Jun 30]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04108156"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2025.0006"},{"key":"#cr-split#-e_1_3_4_63_1.1","unstructured":"F. Hoffmann\u2011La Roche Ltd. A multicenter randomized study in participants with diabetic retinopathy without center\u2011involved diabetic macular edema to evaluate the efficacy safety and pharmacokinetics of ranibizumab delivered via the port delivery system. ClinicalTrials.gov [Internet]. Identifier: NCT04503551. [updated 2025 May 29"},{"key":"#cr-split#-e_1_3_4_63_1.2","unstructured":"cited 2025 Jul 13]. Accessed from: https:\/\/clinicaltrials.gov\/study\/NCT04503551"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.66.7.147"},{"key":"#cr-split#-e_1_3_4_65_1.1","unstructured":"ClinicalTrials.gov [Internet]. Extension study for the port delivery system with ranibizumab (PORTAL). Identifier NCT03683251. Hoffmann-La Roche. [updated 2025 Dec 5"},{"key":"#cr-split#-e_1_3_4_65_1.2","unstructured":"cited 2025 Dec 14]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03683251"},{"key":"e_1_3_4_66_1","volume-title":"Presented at: Euretina Congress","author":"Khanani AM","year":"2025","unstructured":"Khanani AM, Mittra R, Awh CC, et al. First-time long-term efficacy and safety outcomes of PDS patients enrolled in the ladder phase 2 trial of PDS for nAMD followed for up to ~7 years. Presented at: Euretina Congress; 2025 Sep 4\u20137; Paris, France."},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.3928\/23258160-20231016-01"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2022.1091"},{"key":"e_1_3_4_69_1","volume-title":"ASRS 2025 preferences and trends membership survey","author":"Hahn P","year":"2025","unstructured":"Hahn P, editor. ASRS 2025 preferences and trends membership survey. Chicago (IL): American Society of Retina Specialists; 2025."},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2022.05.011"},{"key":"#cr-split#-e_1_3_4_71_1.1","unstructured":"Study of the efficacy and safety of the ranibizumab port delivery system for sustained delivery of ranibizumab in patients with subfoveal neovascular age-related macular degeneration (LADDER). Identifier: NCT02510794. ClinicalTrials.gov [Internet]. [updated 2024 June 3"},{"key":"#cr-split#-e_1_3_4_71_1.2","unstructured":"cited 2025 Oct 6]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02510794"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-023-00446-z"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1177\/2474126419899514"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2017.12.006"},{"key":"#cr-split#-e_1_3_4_75_1.1","unstructured":"Study of zifibancimig in participants with neovascular age-related macular degeneration (BURGUNDY). Identifier: NCT04567303. ClinicalTrials.gov [Internet]. [updated 2024 Sep 9"},{"key":"#cr-split#-e_1_3_4_75_1.2","unstructured":"cited 2025 Oct 6]. Accessed from: https:\/\/clinicaltrials.gov\/study\/NCT04567303"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1063\/5.0264382"}],"container-title":["Expert Opinion on Drug Delivery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17425247.2026.2652029","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T12:39:11Z","timestamp":1780317551000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17425247.2026.2652029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,6]]},"references-count":80,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,3]]}},"alternative-id":["10.1080\/17425247.2026.2652029"],"URL":"https:\/\/doi.org\/10.1080\/17425247.2026.2652029","relation":{},"ISSN":["1742-5247","1744-7593"],"issn-type":[{"value":"1742-5247","type":"print"},{"value":"1744-7593","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,6]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iedd20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iedd20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-11-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}